Preparation of oil-in-water emulsions stabilized by liposomes for vaccine delivery: Expected immune responsesy

Liposome Technology: Interactions of Liposomes with the Biological Milieu

Volumn , Issue , 2006, Pages 361-386

  Matyas, Gary R ^a   Alving, Carl R ^a  

^a Materiel Command   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 44749085042     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (61)

1. Freund J, Casals J, Page-Hosmer E. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc Soc Exp Biol Med 1937; 37:509.
2. Alving CR. Design and selection of vaccine adjuvants: Animal models and human trials. Vaccine 2002; 20:S56.
3. Davenport FM. Seventeen years’ experience with mineral oil adjuvant influenza virus vaccines. Ann Allergy 1968; 26:288.
4. Stuart-Harris CH. Adjuvant influenza vaccines. Bull WHO 1969; 41:617.
5. Chang JCC, Diveley JP, Savary JR, Jensen FC. Adjuvant activity of incomplete Freund’s adjuvant. Adv Drug Deliv Rev 1998; 32:173.
6. Kenney RT, Edelman R. Survey of human-use adjuvants. Expert Rev Vaccines 2003; 2:167.
7. Degen GJ, Jansen T, Schijns VEJC. Vaccine adjuvant technology: From mechanistic concepts to practical applications. Expert Rev Vaccines 2003; 2:327.
8. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed fro veterinary and human vaccines. Vaccine 2001; 19:2666.
9. Sigh M, Srivastava I. Advances in vaccine adjuvants for infectious diseases. Curr HIV Res 2003; 1:309.
10. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine, Vaccine 2001; 19:2673.
11. Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 2003; 21:4234.
12. Podda A, Del Giudice G. MF59-adjuvanted vaccines: Increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003; 2:197.
13. Marshall BC, Adler SP. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: A live attenuated vaccine (towne) and a recombinant glycoprotein vaccine (gB/MF59). Viral Immunol 2003; 16:491.
14. O’Hagan DT, Signh M, Kazzaz J, et al. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with p55 gag antigen. Vaccine 2002; 20:3389.
15. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:randomised controlled trial. Lancet 2004; 364:1411.
16. Garcon N, Heppner DG, Cohen J. Development of RTS, S/AS02: a purified subunit- based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2003; 2:231.
17. Heppner DG Jr., Kester KE, Ockenhouse, et al. Towards an RTS, S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 2005; 23:2243.
18. Vantomme V, Dantinne C, Amrani N, et al. Immunologic analysis of a phase I/II study of vaccination of MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3 positive tumors. J Immunother 2004; 27:124.
19. Vanderpapelière P, Rehermann B, Koutsoukos M, et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine 2005; 23:2591.
20. Harris DT, Matyas GR, Gemella LG, et al. Immunologic approaches to the treatment of prostate cancer. Seminars Oncol 1999; 4:439.
21. Meidenbauer N, Harris DT, Spitler LE, Whiteside TL. Generation of PSAreactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. The Prostate 2000; 43:88.
22. Meidenbauer N, Goodling W, Spitler L, Harris D, Whiteside TL. Recovery of f-chain expression and changes in spontaneous IL-10 production after PSAbased vaccines in patients with prostate cancer. British J Cancer 2002; 86:168.
23. Neidhart J, Allen KO, Barlow DL, et al. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocytemacrophage colony-stimulating factor. Vaccine 2004; 22:773.
24. Fries LF, Gordon DM, Richards RL, et al. Liposomal malaria vaccine in humans:a safe and potent adjuvant strategy. Proc Natl Acad Sci USA 1992; 89:358.
25. Heppner DG, Gordon DM, Gross M, et al. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J Infect Dis 1996; 174:361.
26. Richards RL, Rao M, Wassef NM, Glenn GM, Rothwell SW, Alving CR. Liposomes containing lipid A serve as an adjuvant for induction of antibody cytotoxic T-cell responses against RTS, S malaria antigen. Infect Immun 1998; 66:2859.
27. Richards RL, Swartz GM, Schultz C, et al. Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminum hydroxide and non-pyrogenic liposomal lipid A. Vaccine 1989; 7:506.
28. Muderhwa JM, Matyas GR, Spitler LE, Alving CR. Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery. J Pharm Sci 1999; 88:1332.
29. Matyas GR, Muderhwa JM, Alving CR. Oil-in water liposomal emulsions for vaccine delivery. Methods Enzymol 2003; 373:34.
30. Richards RL, Rao M, Vancott TC, Matyas GR, Birx DL, Alving CR. Liposomes-stabilized oil-in-water emulsions as adjuvants: increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen. Immunol Cell Biol 2004; 82:531.
31. Alving CR, Shichijo S, Mattsby-Baltzer I, Richards RL, Wassef NM. Preparation and use of liposomes in immunological studies. In: Gregoriadis G, ed. Liposome Technology. Vol. III. 2nd ed. Interactions of Liposomes with the Biological Milieu. Boca Raton: CRC Press, 1993:317.
32. Wassef NM, Alving CR, Richards RL. Liposomes as carriers for vaccines. Immunomethods 1994; 4:217.
33. Alving CR, Ownes RR, Wassef NM. Process for making liposome preparation, United States Patent 6,007,838, issued Dec. 28, 1999.
34. White K, Krzych U, Gordon DM, et al. Induction of cytolytic and antibody responses using Plasmodium falciparum repeatless circumsporozoite protein encapsulated in liposomes. Vaccine 1993; 11:1341.
35. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinomaspecific antigen: detection by means of monoclonal antibodies. Proc Nat Acad Sci U.S.A. 1979; 76:1438.
36. White WI, Cassatt DR, Madsen J, et al. Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen. Vaccine 1995; 13:1111.
37. Matyas GR, Alving CR. Protective prophylactic immunity against intranasal ricin challenge induced by liposomal ricin A subunit. Vaccine Res 1996; 5:163.
38. Grit M, Crommelin DJA. Chemical stability of liposomes: implications for their physical stability. Chem Phys Lipids 1993; 64:3.
39. Thérien HM, Shahum E. Importance of physical association between antigen and liposomes in liposomes adjuvanticity. Immunol Lett 1989; 22:253.
40. Alving CR. Liposomes as carriers of antigens and adjuvants. J Immunol Meth 1991; 140:1.
41. Alving CR, Richards RL, Hayre MD, Hochmeyer WT, Witz RA. Liposomes as carriers of vaccines: development of a liposomal malaria vaccine. In: Gregoriadis G, Allison AC, Poste G, eds. Immunological Adjuvants and Vaccines. New York: Plenum Publishing Corp., 1989:123.
42. Richards RL, Hayre MD, Hockmeyer WT, Alving CR. Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Infect Immun 1988; 56:682.
43. Baker PJ. Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes. Infect Immun 1990; 58:3465.
44. Baker PJ, Fauntleroy MB, Stashak PW, Hiernaux Jr, Cantrell JL, Rudbach, JA. Adjuvant effects of trehalsoe dimycolate on the antibody response to type III pneumococcal polysaccharide. Infect Immun 1989; 57:912.
45. Baker PJ, Hraba T, Taylor CE, et al. Structural features that influence the ability of lipid A and its analogs to abolish expression of suppressor T cell activity. Infect Immun 1992; 60:2694.
46. Baker PJ, Hraba T, Taylor CE, et al. Molecular structures that influence the immunomodulatory properties of the lipid A and inner core region oligosaccharides of bacterial lipopolysaccharides. Infect Immun 1994; 62:2257.
47. Lowry OH, Rosenbrough NJ, Farr AL. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265.
48. Koppenhage FJ, Storm G, Underberg WJ. Development of a routine analysis method for liposome encapsulated recombinant interleukin-2. J Chromatogr B Biomed Sci Appl 1998; 716:285.
49. Lutsiak ME, kwon GS, Samuel, J. Analysis of peptide and lipopeptide content in liposomes. J Pharm Pharm Sci 2002; 5:279.
50. Laemmli UK. Cleavage of structural proteins during the assembly of the head of baceriophage T4. Nature 1970; 227:680.
51. Wessel D, Flügge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 1984; 138:141.
52. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U.S.A. 1979; 76:4350.
53. Gerlach E, Deuticke B. Eine einfache methode zur mikrobestimmung von phosphate in der papierchromatographie. Biochem Zeischrift 1963; 337:477.
54. Muderhwa JM, Wassef NM, Spitler LE, Alving CR. Effects of aluminum adjuvant compounds, tweens, and spans on the stability of liposome permeability. Vaccine Res 1996; 5:1.
55. Zlatkis A, Zak B, Boyle AJ. A new method for the direct determination of serum cholesterol. J Lab Clin Med 1953; 41:486.
56. Mattsby-Baltzer I, Alving CR. Lipid A fractions analysed by a technique involving thin-layer chromatography and enzyme-linked immunosorbent assay. Eur J Biochem 1984; 138:333.
57. Hagen SR, Thompson JD, Snyder DS, Myers KR. Analysis of a monophosphoryl lipid A immunostimulant preparation from Salmonella minnesota R595 by high-performance liquid chromatography. J Chrom 1997; 767:53.
58. Parleasak A, Bode C. Lipopolysaccharide determination by reversed-phase highperformance liquid chromatography after fluorescence labeling. J Chrom 1995; 711:277.
59. Kiang J, Wang LX, Tang M, Szu SC, Lee YC. Simultaneous determination of glucosamine and glucosamine 4-phosphate in lipid A with high-performance anion-exchange chromatography (HPAEC). Carbohyd Res 1998; 312:73.
60. Woodard LF, Jasman RI. Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants. Vaccine 1997; 15:1773.
61. McElrath MJ. Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol 375; 1995:6.